Income Statement Presentation 2023

2023: Key late-stage news flow* Regulatory Phase III / pivotal readouts Compound Hemlibra Polivy + R-CHP Vabysmo Tecentriq Glofitamab Xofluza Tecentriq + Avastin Tecentriq + chemo Tecentriq Tecentriq + chemo Tiragolumab + Tecentriq Tiragolumab + Tecentriq + chemo Venclexta + dexamethasone Venclexta + azacitidine Alecensa Phesgo OBI (on body injector) Crovalimab Glofitamab + GemOx Lunsumio + Polivy Delandistrogene moxeparvovec (SRP-9001) Ocrevus 6m SC Indication Moderate hemophilia A 1L DLBCL RVO Subcutaneous administration 3L+ DLBCL Influenza (paediatric 1+ yrs.) Adjuvant HCC Neoadjuvant/adjuvant TNBC Adjuvant SCCHN Adjuvant TNBC 1L PDL 1+ NSCLC 1L esophageal cancer t(11;14) R/R MM 1L high risk MDS Adjuvant ALK+ NSCLC HER2+ BC PNH 2L+ DLBCL Milestone EU approval US approval US approval/EU filing US approval/EU filing US/EU approval EU approval Ph III IMbrave050 Ph III GeparDouze/NSABP B-59 Ph III IMvoke010 Ph III IMpassion030 Ph III SKYSCRAPER-01 Ph III SKYSCRAPER-08 (China only) Ph III CANOVA Ph III VERONA Ph III ALINA Ph I (pivotal) Ph III COMMODORE 1/2 Ph III STARGLO Ph III SUNMO** Ph III EMBARK Ph III OCARINA II 2L+ DLBCL DMD RMS/PPMS Stroke patients 4.5-24h Ph III TIMELESS DME Ph III PAGODA TNKase Susvimo Susvimo DR Xolair Food allergy Outcome studies are event-driven: timelines may change; i ** Results are event-driven; read-outs expected in 2023/24 Ph III PAVILION Ph III OUTMATCH Roche 35

View entire presentation